first glp 1 drug Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment History of glucagon-like peptide-1 receptor
Description
Over the course of 2128 days, SAR425899 evidences maximal BW reduction of 5.32 kg in healthy/overweight patients, while overweight/obese patients with T2D experienced maximal BW reductions of 5.46 kg along with significant reductions in fasting plasma glucose and glycated hemoglobin [177]

doi: 10.1016/j.cmet.2018.03.001

Vishal Manchanda, equity research analyst-pharma, Systemix Group, explains the significance: "The advantage with non-peptide is that they can be quickly scaled up and cost less to produce." Swapnil Shah, MD of Senores Pharma, adds a cautionoral GLP-1s are not standard small molecules

Swipe through to discover 6 numbers that can reveal what's really going on beneath the surface

What gives it a fearsome reputation is its venomous biteit latches on and chews to deliver its venom

Hsu CY, McCulloch CE, Iribarren C et al
